Hit-to-lead in drug discovery: analytical strategies for hit validation and lead optimization

Every small-molecule program begins with a deceptively simple question: Does this compound actually bind the target, and can it become a drug? Turning a screening signal into a molecule worth advancing is one of the most consequential inflection points in hit-to-lead work in drug discovery. Early biophysical triage is only half the story. Once a hit is confirmed, the analytical demands shift toward the bioanalytical data that determines whether a molecule is truly developable.

What are hits in drug discovery? From screening libraries to confirmed candidates

In practical terms, a hit is any compound showing reproducible activity against a therapeutic target during a primary screening process in drug discovery, which might be a high-throughput campaign covering a million-plus compounds, or it might come from a DNA-encoded library or a fragment collection. A raw screening signal, however, is not automatically a genuine binder. Assay artifacts such as colloidal aggregation and fluorescence interference can generate false positives indistinguishable from true engagement on a single readout.

This is why the hit identification process in drug discovery does not end at the primary screen. Robust programs apply a hit confirmation assay strategy that layers orthogonal readouts before committing resources:

Structural methods (X-ray crystallography, cryo-EM) resolve a binding pose but do not by themselves establish affinity.
Solution-phase assays (Nuclear Magnetic Resonance, NMR, Surface Plasmon Resonance, SPR, and Isothermal Titration Calorimetry, ITC) measure binding affinity directly, though they are not immune to artifacts of their own, which is why cross-validation across methods still matters.
Functional and cellular assays verify that in vitro activity translates into the expected biological effect.

Hit-to-lead transition: criteria, decision gates, and the rule of 3

The difference between hit and lead in drug discovery involves both molecular property changes and characterization depth. A lead typically shows improved ligand efficiency and a defined structure-activity relationship, along with early evidence of selectivity against relevant off-targets, properties a confirmed hit does not yet need to demonstrate. Reaching the hit-to-lead stage in drug discovery is a decision gate that usually requires:

Potency gains that track with ligand efficiency, not just added molecular weight: the compound binds more efficiently per atom, not simply harder because it got bigger.
A minimum pharmacophore: the core set of interactions required for activity, defined clearly enough to guide analog design.
Physicochemical properties trending toward the oral bioavailability space, when oral delivery is the program’s target route.

Fragment hits come from libraries built around the rule of 3, usually applied in drug discovery programs, although it is used more as a screening-stage guideline than a hit-to-lead decision itself. In practice, only two of its four original criteria really stuck: molecular weight under 300 Da and calculated logP under 3. The rule’s own originators have since noted that the other two, hydrogen bond donors and acceptors capped at 3 each, never caught on the same way, partly because there’s no consistent way to count them. Fragments bind weakly by design, so hit-to-lead optimization for fragment-derived hits usually means synthesizing 50 to 100 analogs to push affinity from the millimolar into the nanomolar range, with ligand efficiency, not raw potency, as the guiding metric throughout.

Analytical methods for hit characterization and structural confirmation

Hit validation in drug discovery relies on techniques that go beyond a single readout. Nuclear Magnetic Resonance and structural methods dominate early biophysical triage, but mass spectrometry (MS) applications carry much of the analytical weight once a series enters iterative synthesis.

For covalent fragments, where the interaction is irreversible, intact protein MS detects the adduct as a clear mass shift, and tandem MS maps exactly which residue was labeled. Just as critically, LC-MS confirms that every newly synthesized analog matches its intended structure and purity before it reaches a potency assay. This layered approach is especially critical in fragment-based drug discovery, where weak initial affinities make single-method conclusions unreliable.

Once a series clears this stage, the analytical focus shifts. Structure/activity relationship data from hit confirmation hands off to a more bioanalytically intensive question: is this molecule stable, selective, and absorbable enough to survive contact with a living system?

ADMET profiling and lead optimization: balancing potency with developability

Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling in drug discovery evaluates the pharmacokinetic and safety properties that decide whether a potent compound can actually survive contact with a living system, not just bind its target in a dish. In other words, this is where the lead optimization process earns its name.

Left unaddressed until late, these liabilities remain a leading cause of clinical-stage attrition. Medicinal chemistry lead optimization, therefore, runs potency and developability tracks in parallel, generating analogs that need the kind of high-throughput, UPLC-MS/MS-based bioanalytical support that has become the backbone of modern discovery labs:

Metabolic stability and CYP (cytochrome P450, the liver enzymes that metabolize most drugs) inhibition: two of the most established ADME endpoints, routinely profiled at high throughput via LC-MS/MS across discovery programs.
Lipophilic efficiency: one metric weighing potency against rising molecular weight or logP, flagging gains that cost too much.
Multi-parametric filtering: screening candidates against drug-like properties according to thresholds established in drug discovery, before proceeding with their synthesis.

Modern discovery bioanalysis groups report developing hundreds of LC-MS/MS methods and processing thousands of samples weekly, with turnaround times of one to two business days. Without that throughput, even a well-designed chemistry cycle stalls waiting for data.

How analytical CROs accelerate hit-to-lead campaigns

Few teams can staff the full breadth of high-throughput bioanalytical methods drug discovery programs require in-house, particularly the LC-MS/MS capacity needed to turn around metabolic stability, permeability, and biomarker data at the speed lead optimization cycles demand. This is where an experienced analytical CRO partner adds real value: validated, high-throughput bioanalytical workflows that scale with a program without requiring every sponsor to build that infrastructure internally.

At AMSbiopharma, we support lead optimization and candidate profiling with UPLC-MS/MS bioanalytical services, covering DMPK, biomarker analysis, and impurity and quality control testing toward IND-enabling studies.

References

Grosjean H, Biggin PC. Developments and challenges in hit progression within fragment-based drug discovery. Nat Commun. 2026 Jan 31;17(1):2226. doi: 10.1038/s41467-026-68941-z

Jhoti H, Williams G, Rees DC, Murray CW. The ‘rule of three’ for fragment-based drug discovery: where are we now? Nat Rev Drug Discov. Published online 12 July 2013. doi: 10.1038/nrd3926-c1

Nippa DF, Atz K, Stenzhorn Y, Müller AT, Tosstorff A, Benz J, Binch H, Bürkler M, Haider A, Heer D, Hochstrasser R, Kramer C, Reutlinger M, Schneider P, Shema T, Topp A, Walter A, Wittwer MB, Wolfard J, Kuhn B, van der Stelt M, Martin RE, Grether U, Schneider G. Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization. Nat Commun. 2025 Nov 26;16(1):11646. doi: 10.1038/s41467-025-66324-4

Shou WZ. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal. 2020;10(3):201-208. doi: 10.1016/j.jpha.2020.05.004

Santiago BG, Eisennagel SH, Peckham GE, et al. Perspective on high-throughput bioanalysis to support in vitro assays in early drug discovery. Bioanalysis. 2023;15(3):177-191. doi: 10.4155/bio-2022-0207

By AMSbiopharma